Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 232 +/- Trametinib in R/R AML
NCT02016729Phase 1Completed
- Sponsor
- Kartos Therapeutics
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navtemadlin in acute myeloid leukemia (AML) (2 arms), sponsored by Kartos Therapeutics. Primary endpoints: Safety and Tolerability of AMG 232 at 36 months, Pharmacokinetics of AMG 232 at 36 months and 1 more. Started Apr 2014; status: completed.
02
Drugs
navtemadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02016729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016729.